Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

AstraZeneca capped off a hectic Monday with a deal potentially totaling $1.35 billion with South Korean biotech Alteogen to advance novel subcutaneous therapies for cancer. The pact, reported by ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday ...